INTRODUCTION
The association between Down's Syndrome [DS] and Alzheimer's Disease [AD] has been well recognized for some time now. Senile plaq ues were first described in DS brains in 1921 by Struwe. In 1948 J ervis described clinical deterioration and Alzheimer's neuropathology in DS. It is also suggested now that this association is two-sided! On o ne hand individ ua ls with DS tend to develop AD at so m e point in th eir lives ifthey survive long enough (1) (2) (3) (4) (5) . On the other hand, there have been some reports of h igh er t ha n expected frequencies of DS in families with AD (5, 6) . Mo r e rece ntly, a gene defect associated with the " fam ilial Alzheimer's Disease" (FA D) has been mapped to chromosome 21 , a chromosome related to DS (7, 8) . Although some of th ese find ings are disputed, it is worthwhile to review current knowledge in th e relati onsh ip between these two conditions, while awaiting further information abo ut cli nicopatho logical and genetic association between them.
T h is overview describes each of these two conditions briefl y in relation to th e other and then examines th e association and th e implica tio ns of th is association between them.
In this overview , th e term A D is used to refer to ind ividuals with a prov isional diagnosis of Primary Degenerative Dementia of Alzheimer's type.
Alzheimer's Disease-Diagnostic Accuracy

JEFFERSON JOURNAL O F PSYCHI AT RY
Primary Degenerative Dementia-Alzheimer's type, is a neuropatholog ical diagnosis. It is the commonest cause of dementia in the general populatio n an d is frequently encountered entity in clinical settings in individuals presenting wit h symptoms of dementia. AD remains mainly a diagnosis of exclusio n . A ntemortem diagnostic accuracy depends on variety of factors , including patient selection, diagnostic criteria and assessment methods. The postmortem hi stologica l verification of the diagnosis is therefore the gold standard (9) .
AD in persons with a normal karyotype usually begins with learning and memory deficits, and slowly progresses to involve all the aspects of intellectual activity including judgement, calculation and language (10) . In the early stages, psychometric assessment indicates more profound impairment of ideomo tor performance than language (10). Dalton et al (11) reported that memor y loss, depression and disorientation were the most frequently reported early sym ptoms of AD in patients with a normal karyotype. In comparison, th ese are th e least frequently reported symptoms in DS individuals who developed AD (1 1).
There have been several reports systematically describing fun ctional and clinical disturbances in AD in the general population and the reader is advised here to refer to the relevant literature for a detailed description.
The differential diagnosis of dementia has remained a challenge. There are several assessment methods now available which are reasonably sensiti ve and specific in differentiating causes of dementia. Many in vestigators have used behavioral observations (12) , while the others have used sophisticated neurodiagnostic tools including Computed Tomography (CT), Positron Emission T omography (PET), Single Photon Emission Computed Tomography (SPECT), Xe non inhalation, Electroencephalography (EEG), Evoked potentials and co mb ina tions of these for the etiologic diagnosis of dementia (9) . However because o f factors such as cost/benefit ratio, sensitivity, specificity and accessibil it y, these meth od s have remained research tools at large. At present, there is no 'go ld standard' criterion or test for the determination of etiology of dementia in clinical settings. The etiologic diagnosis of dementia is critical because some o f th e o ther ca uses are treatable or at least controllable to some extent.
As mentioned earlier, diagnostic accuracy of AD depends on a variety of factors. Tiemay et al (13) reported that accuracy varied between 81 % and 88 % in clinical settings. A retrospective review b y Bolier et a l ( 14) and th e report o f Joachin et al (15) suggest that elaborate clinical investigations m ay no t enhance diagnostic accuracy. In research settings the diagnostic acc uracy may exceed 90 % (9). Morris et al (16) reported 100% accuracy in a sel ected sa mple of 31 cases with strict inclusion and exclusion criteria with out any reference to neuropsychological test performance. These findings app ly to th e general population with normal or unknown karyotype, where, in ab sence of a 'gold standard' , the selection of a sample is extremely difficult. T he issue of d iagnost ic accuracy is much more difficult, particularly in the early stage of AD, in t he individuals with DS.
Genetics ofAD
A genetic basis for some cases of AD was first suggested in 19 33 (17) . There are case reports describing ' fa m ilial Alzheimer's disease' [FA D] (18, 19) , characterized by early onset dementia. Brietner et al in recent studies (20, 2 1) indicated that the majority of these cases are inherited as an autosomal dominant mutation. In a more recent study (22) they reported a striking increase in cum ula tive incidence of AD-like illness among the first degree relati ves of AD probands. Bird et al (23) noted significant phenotypic heterogeneity in 180 deme nt ed individuals from 24 kindreds. They noted clinical and neuropathological d ifferences among families with AD. They raised questions whether th ere is more than one type of AD, even among FAD patients and whether th e phen otypic heterogeneity represents a genetic heterogeneity or is merely an epiphe nomenon. St. George Hyslop et al (8) recently reported FAD linked to two chromosome 21 q21 loci in four families. One of these two markers is link ed to the amyloid B gene. Thus the q21 region of the long arm of chromosom e 2 1 seems to be of particular relevance to AD. Some groups of pedigrees have been assembled in which autopsy determined AD appears to be inherited as an autosomal dominant trait (24) . However, the findings of genetic linkage were disputed by Schellenberg et al (24) . They found no evidence of linkage bet ween FAD and chromosome 21 markers, including the am yloid B gene. T hey obtained strong evidence for genetic heterogeneity when they compar ed their study group to St. George Hyslop et aI's group. In this study, most of the evidence for exclusion of genetic linkage came from presenile onset families , although the age of onset was higher than that in St. George H yslop et aI's group. They mentioned the possibility that the gene in chromosome 2 1 may account only for very early onset FAD.
There also are some other results suggesting genetic invol ve ment in AD . From Heston et aI's careful genetic study (3) of 125 families, so me relatives of younger probands from autopsy proven AD appear to be at increased risk of Down's syndrome, of myeloproliferative disorders and immune system d isorders. Kallmann's (25) investigation oftwin pairs suggested monozygotic co ncordance in AD. All these evidences suggest a genetic component in at least some cases of AD. The exact nature of such genetic contribution is yet to be kno wn .
Down's Syndrome
Ever since the classical description of 'Mongolism ' by Langdon Down in 1866, this has remained the most discussed and the most investigated syndrome in the field of mental retardation. The presence of an extra small ch r omoso me was reported by Lejeune in 1959, and was later identified as ch romosome 21 .
These patients present with a var iety of physical characte ris tics and clini cal problems.
Only two decades ago, very few DS individuals survived through midad u lthood because of associated congenital heart di sea se , recurre nt infectio ns and a variety of other problems. With advancing health care an d medical te chnology, more and more of these individuals surv ive until 40 years and be yond. According to recent data by Baird and Sado vn ick (33), 80 % of DS patients without congenital heart disease survive pa st th e age of 30 years. Mo re than 50 % of their DS patients reached their 50 's and 13. 5 % reached age 68. These observations are significant in relation to the development of AD neuropathology in these individuals.
Studies have shown a higher than average incidence of h ypoth yr o id ism (34-37), and at least average incidence, if not higher, of depression (38) in DS. Hypothyroidism in DS is expressed usually as abnormality in o ne or mo re thyroid function tests whereas clinically, most of these individuals are asymptomatic. Hollingworth et al (39) compared T4, T3 and TSH levels in 60 DS patients to controls and did not find a significant difference. Howe ver, six DS patients had goiter and seven had exophthalmos without goiter. Man i (40) studied 55 adult hospital DS patients; almost all of them were 40 yea rs or over. H e found a high frequency of clinical features suggesting h ypothyro idi sm. H e recommended screening th yroid function in all DS individuals over 40.
In spite of the lack of evidence pointing to specific ca uses of hypoth yroidism , so m e ha ve suggested autoimmunity as an etiologic facto r fo r underactivity of the th yroid gland (40) . Most of these stu d ies fou nd antibo dies to thyroid tissue in DS patients. Increased rates of lymphocytic leukemia and ot her malignancie s and a higher incidence of viral and bacterial infectio ns have also been reported (41-43). A higher incidence of congenital hypothyr o id ism had also been reported (44) .
In 1981 , Harrell et al (45) reported benefici al effects of vita m ins, minerals and th yroid compound in improving intellectual fu nction ing in pe rsons wit h DS. They did not evaluate th yroid function prior to therapy. Subsequent att e mpts to replicate these results with vitamin and mineral therapy were un successful (46) . Tiurosh and Toub et al (47) , in a double blind cross-o ver drug-placebo trial, stu d ied a small sample to assess the efficacy of short term th yr oid su pplement in DS individuals with low borderline th yroid fun ction. They fo und no significant gains with thyroid supplement. Replication of similar results o n a larger sample with more attention towards symptoms of dementia is needed to clarify the indications for thyroid supplement in DS individuals.
A high prevalence of psychiatric disorders in th e mentall y retarded, including those with DS, has been reported (4 8). Several case reports of major depression in DS patients hav e been published (49 ,50) , a lthoug h th ere have been so me unusual presentations and disagr eements in th e d iagnosis of affective di sorders in moderate to se vere retardation. Estimates of th e preva lence of depression in DS are not availabl e at present. Consid ering men ta lly re ta rded of all th e different etio logies as a single group, it seems like ly that affective di so rders are at least as common in th ese indi viduals as in general population (38) . This is particularly significant in DS pati ent over age of 40, sinc e it complicates the detection of early AD .
Alzheimer's Disease in Down's Syndrome
Alongside the clinical obser vations and genetic stu d ies in AD patients, there ar e several reports on DS individuals that sugges t a str iking association between these two conditions. However, th e nature and th e clinical and genetic implications of this association remains elusive. Neuropathologica l cha nges of AD in brains of DS individuals have been r eported for more than 50 years now. Since Struwe 's report in 1929, it is well recognized fr om severa l stu d ies t hat virtually all DS individuals 37 years or over develop AD neuropathology, na mely, extensive neurofibrillatory degeneration and senile plaques, throughout wides pread regions of neocortex (26, 27) ; Certain dermatoglyphic patterns are co mmon in DS patients (28, 29, 30) , and the extension of th ese stu d ies to their parents showed unusual combinations of dermatoglyphic patterns in pare nt s, pa rticularly in a parent in whom non-disjunction occurred (31) . Dermato glyph ic changes sim ilar to DS were also observed in AD by Weinrab wh o repo rted a high frequency of ulnar loops on fingertips of both AD and DS patients (32) . These and other evidences are becoming clearer as the surv ival of DS individuals is prolonged.
Clinically, some investigators have observed difference s in sympto ms of AD in DS patients and in general population. Dalton et al (11) reviewed 35 DS cases from several case reports. They examined 18 descriptive terms of fun ct ion al an d clinical features in these cases excluding language based di sturban ces. They found that the most frequently reported c1inico-functional ex p ression in these cases was clinical seizures (87.8 %); followed by personality changes (45 .5 %) and focal neurological signs (45.5 %). The most frequentl y reported sym ptoms in patients with AD in general population-i.e . memory loss, depressio n and disorientation-were the least frequently reported in persons with A D in DS. Besides, differences were noted in self help skills and level of ac tivity in th ese two groups with AD . Although such comparison between unmatch ed groups and variable interpretations of retrospective clinical records can provide som e direction for further research , it serves little in clarifying the confusion regarding the natural history of AD in DS.
Only one prospective study on AD in DS is reported in lit erature (5 1). In this study of 49 clinically demented DS indi viduals ove r age 35 followed longitudinally, the average age of dementia onset was 54.2 + 6.1 years, which is much earlier than AD in the general population. In 23 patien ts who died, the average duration was 4.6 + 3.2 years with no sign ificant difference betwee n the sexes. This study was also able to delineate seve ra l features of A D in the ir DS patients. (i) The first signs of dementia in DS-changes in perso nal ity such as irritability and emotional labil ity in most cases in th eir study populationcorrelate wit h the lat e features of AD in general populati on . (ii) There is a latent period of 2 to 3 decades between the time of onset of neuropat ho logica l changes and clinical symptoms. (iii) Prevalence of dementia increases wit h age. (iv) There is higher incidence of se izu res in th ese individuals as compared to AD patients in general population . (v) T wenty percent of DS outpatients with deme nt ia a lso developed Parkinson's dis ea se.
DISCUSSION
The available information about the association between A D and DS raises many questions and hypotheses, most of which still remain unanswered . The differences noted in clinical features of AD in DS and in persons with normal karyotype poses a question if there is a different etiology and pathogen esis of A D in these two groups (11) . This questions the significance of pathological changes and the clinicopathological correlation in AD. The issue is further co mplicated by findings of changes identical to AD in many elderly brains in absence of clinical symptoms. Interestingly enough, there are at lea st two case reports of DS patients-one 49 year s and the other 47 years of age-who showed no neuropathology of AD in brain on autopsy (52, 53) . The prevalence of AD increases with age in DS as well as general population and it is assumed that th e agin g process begins early and progresses rapidly in DS individuals (54 ) . These obse rvations support Gowers' concept with the implication that AD represents merely a precocious aging of central nervous system (55) . If so, one can assume th at every individual who lives long enough will develop AD at some point. It may be possible that the symptoms appear only when brain changes are extensive enough or when they involve certain brain areas, such as hippocampus.
However, from epidemiological evidence and clinical observations, there is little doubt that a disease process is involved in AD. Besides th e issue of ca usal factors it also remains to be seen if there are separate factors that contro l th e age of onset in AD .
Almost all DS individuals show AD neuropathology at so me point , and up to 85 % of these-presumably all if they lived long enough-develop AD (5 1). Theoretically it seems possible to detect AD in its early phase and to delineat e its natural history in this cohort. In that case, the idea of detecting a " he ra ld sign" that predicts or signals the onset of clinical AD appears promising. An indi vid ual sign which increases in prevalence with advancing age ma y need careful scrutiny. Examples of such signs would include primitive reflexes, face -hand te st etc., of course, this would require several detailed longitudinal observati ons.
As mentioned earlier, there are strong indications of a genetic link betwee n AD and DS. Although a chromosomal abnormality in AD needs furth er confirmation, if present, it could be of tremendous help in screen ing potential pare nt s with high risk pregnancies. For clinicians, it would be important to include spec ific questions in obtaining the famil y history of individuals with these con di t io n s. In co n cl us io n, th ere is no d oubt about th e r el a ti o n sh ip between AD a n d DS , but t her e are se ve r a l unanswered que stio n s regarding the nature of this relationship. The issu es of o r ig in , pathogenesis a n d th e natural history of dementia in DS awaits furth er prospective stud ies. Th e g roup of DS individuals se e m s a readily available " id ea l" co h o r t because of th eir a lmost certainly known outcome. Obviously, this will be a promising area of r ese arch in the field of ps ychiatry and the study of mental retardation .
